Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 48
Summary
- Conditions
- Myelodysplastic Syndromes
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01913951
- Collaborators
- Sunesis Pharmaceuticals
- Investigators
- Principal Investigator: Meagan Jacoby, M.D., Ph.D. Washington University School of Medicine
Get Well Soon